X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1811) 1811
Book Review (149) 149
Newsletter (120) 120
Publication (52) 52
Conference Proceeding (15) 15
Newspaper Article (10) 10
Dissertation (5) 5
Magazine Article (5) 5
Book Chapter (3) 3
Trade Publication Article (2) 2
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fluvastatin (1787) 1787
index medicus (1194) 1194
humans (940) 940
male (673) 673
female (552) 552
statins (463) 463
middle aged (458) 458
pharmacology & pharmacy (393) 393
simvastatin (374) 374
pravastatin (364) 364
cholesterol (341) 341
fatty acids, monounsaturated - therapeutic use (334) 334
indoles - therapeutic use (334) 334
atorvastatin (318) 318
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (316) 316
adult (314) 314
fatty acids, monounsaturated - pharmacology (314) 314
indoles - pharmacology (314) 314
animals (309) 309
aged (286) 286
hypercholesterolemia (248) 248
cardiac & cardiovascular systems (245) 245
lovastatin (241) 241
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (230) 230
anticholesteremic agents - therapeutic use (224) 224
atherosclerosis (211) 211
hypercholesterolemia - drug therapy (201) 201
abridged index medicus (183) 183
treatment outcome (175) 175
cholesterol, ldl - blood (172) 172
fatty acids, monounsaturated - administration & dosage (158) 158
indoles - administration & dosage (158) 158
rats (155) 155
prevention (153) 153
drug therapy (148) 148
risk factors (148) 148
therapy (147) 147
research (145) 145
cholesterol - blood (138) 138
peripheral vascular disease (138) 138
antilipemic agents (131) 131
dose-response relationship, drug (123) 123
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (123) 123
analysis (121) 121
lipids (121) 121
statin (117) 117
fatty acids, monounsaturated - adverse effects (115) 115
indoles - adverse effects (115) 115
coa reductase inhibitors (113) 113
pharmacokinetics (113) 113
anticholesteremic agents - pharmacology (112) 112
drug interactions (112) 112
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (112) 112
triglycerides - blood (111) 111
in-vitro (108) 108
double-blind method (107) 107
medicine, general & internal (106) 106
hydroxymethylglutaryl-coa reductase inhibitors (104) 104
drug therapy, combination (103) 103
time factors (103) 103
risk (102) 102
hypercholesterolemia - blood (99) 99
disease (96) 96
lipids - blood (96) 96
anticholesteremic agents - administration & dosage (95) 95
efficacy (93) 93
hmg-coa reductase (93) 93
dosage and administration (89) 89
expression (88) 88
hyperlipidemias - drug therapy (88) 88
rosuvastatin (87) 87
low-density-lipoprotein (86) 86
medicine & public health (86) 86
coronary-heart-disease (84) 84
transplantation (84) 84
anticholesteremic agents - adverse effects (83) 83
drugs (81) 81
safety (81) 81
cells, cultured (79) 79
cholesterol, hdl - blood (79) 79
mice (79) 79
cardiovascular disease (78) 78
myocardial-infarction (77) 77
mortality (76) 76
surgery (76) 76
prospective studies (75) 75
care and treatment (74) 74
hyperlipidemia (74) 74
inflammation (74) 74
medicine (74) 74
simvastatin - therapeutic use (74) 74
atorvastatin calcium (73) 73
medicine, research & experimental (73) 73
pravastatin - therapeutic use (72) 72
health aspects (70) 70
oxidative stress (70) 70
medical research (69) 69
metabolism (69) 69
events (66) 66
pharmacology/toxicology (66) 66
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1866) 1866
Japanese (20) 20
German (17) 17
Russian (16) 16
Chinese (9) 9
Spanish (8) 8
French (7) 7
Czech (5) 5
Italian (2) 2
Korean (2) 2
Polish (2) 2
Portuguese (2) 2
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Brain Research Bulletin, ISSN 0361-9230, 10/2018, Volume 143, pp. 1 - 8
Alzheimer’s disease (AD) is one of the severe chronic diseases characterized with amyloid beta (Aβ) aggregation and formation of senile-plaque (SP) like... 
Amyloidogenesis | Fluvastatin | Alzheimer’s disease | Copper | Zinc | Cholesterol
Journal Article
TRANSPLANTATION, ISSN 0041-1337, 01/2015, Volume 99, Issue 1, pp. 17 - 20
Prospective clinical trials are constructed with high levels of internal validity. Sample size and power considerations usually address primary endpoints.... 
SURGERY | FLUVASTATIN | IMMUNOLOGY | RENAL-TRANSPLANT RECIPIENTS | TRANSPLANTATION
Journal Article
Dental Materials Journal, ISSN 0287-4547, 2012, Volume 31, Issue 3, pp. 489 - 493
Journal Article
Toxicology Letters, ISSN 0378-4274, 07/2000, Volume 116, Issue 1-2, pp. 369 - 377
The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a key regulator in cholesterol biosynthesis and HMG CoA reductase inhibitors (statins)... 
fluvastatin
Journal Article
Journal of Molecular and Cellular Cardiology, ISSN 0022-2828, 04/2019, Volume 129, p. 314
Statins, in addition to their cholesterol lowering effects, can prevent isoprenylation of Rab GTPase proteins, a key protein family for the regulation of... 
Proteins | Fluvastatin | Anti-arrhythmia drugs | Research institutes | G proteins
Journal Article
Pathogens (Basel, Switzerland), ISSN 2076-0817, 08/2019, Volume 8, Issue 3, p. 122
causes a deadly disease called primary amoebic meningoencephalitis (PAM). Even though PAM is still considered a rare disease, the number of reported cases... 
Naegleria | therapeutics | fluvastatin | encephalitis | statins
Journal Article
Life Sciences, ISSN 0024-3205, 04/2019, Volume 222, pp. 212 - 220
Fluvastatin reduces tumor proliferation and increased apoptotic activity in various cancers. Special AT-rich sequence binding protein 1 (SATB1) is a genome... 
Non-small-cell lung cancer | Fluvastatin | Wnt/β-catenin pathway | SATB1 | MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | METASTASIS | Wnt/beta-catenin pathway | STATINS | INVASION | THERAPY | GASTRIC-CANCER | PHARMACOLOGY & PHARMACY | UP-REGULATION | TUMOR-GROWTH | EXPRESSION | PROGRESSION | A549 Cells | Lung Neoplasms - drug therapy | Matrix Attachment Region Binding Proteins - metabolism | Humans | Lung Neoplasms - metabolism | Matrix Attachment Region Binding Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - metabolism | Down-Regulation - drug effects | Down-Regulation - physiology | Fluvastatin - pharmacology | Phenotype | Neoplasm Invasiveness - pathology | Cell Line, Tumor | Carcinoma, Non-Small-Cell Lung - drug therapy | Fluvastatin - therapeutic use | Genes | Genomics | Development and progression | Genetic aspects | Metastasis | Genetic transcription | Lung cancer, Non-small cell | Protein binding | Antilipemic agents | Cell proliferation | Wnt protein | Transcription | Lung | Lung cancer | Genomes | Metastases | Anticancer properties | Proteins | Time dependence | β-catenin | Mechanics (physics) | Transfection | Inhibition | Statins | Phenotypes | Nucleotide sequence | Amino acid sequence | Polymerase chain reaction | Molecular modelling | Antitumor activity | Viability | Cancer | Tumors | Apoptosis | Index Medicus
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2018, Volume 12, pp. 3491 - 3499
Background: In this study, fluvastatin (FVT) nanosuspensions containing cyclodextrin were developed to improve oral bioavailability. Methods: FVT... 
Fluvastatin | Bioavailability | Nanosuspensions | HP-β-CD | Irritation test | DRUG | nanosuspensions | CHEMISTRY, MEDICINAL | HP-beta-CD | fluvastatin | bioavailability | IMPROVEMENT | PHARMACOLOGY & PHARMACY | PARTICLE-SIZE | irritation test | DISSOLUTION RATE | DELIVERY | Fluvastatin - pharmacokinetics | Suspensions - chemistry | Nanoparticles - chemistry | Rats, Wistar | Drug Stability | Suspensions - administration & dosage | Cyclodextrins - pharmacokinetics | Drug Tolerance | Rats | Biological Availability | Fluvastatin - administration & dosage | Animals | Cyclodextrins - administration & dosage | Cyclodextrins - chemistry | Suspensions - pharmacokinetics | Fluvastatin - chemistry | Nanoparticles - administration & dosage | Hydrogen-Ion Concentration | Powders | Diffraction | Analysis | X-rays | Calorimetry | Cyclodextrins | Antilipemic agents | Particle size | Drug delivery systems | Size distribution | Mucosa | Gastric mucosa | X-ray diffraction | Villus | Heat measurement | Hemorrhage | Powder | Intestine | Controlled release | Freeze-drying | Erosion | Irritation | Differential scanning calorimetry | Pharmacodynamics | X ray powder diffraction | Pharmacology | High pressure | Cyclodextrin | Particle size distribution | Transmission electron microscopy | In vivo methods and tests | Pharmacokinetics | Cardiovascular disease | Nanoparticles | Drug dosages | Homogenization | Surfactants | Index Medicus
Journal Article
International Journal of Pharmacy and Technology, 09/2016, Volume 8, Issue 3, pp. 19111 - 19121
Journal Article
AMERICAN JOURNAL OF CARDIOLOGY, ISSN 0002-9149, 07/2003, Volume 92, Issue 2, pp. 152 - 160
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and... 
LOVASTATIN | DENSITY-LIPOPROTEIN CHOLESTEROL | CARDIAC & CARDIOVASCULAR SYSTEMS | DOUBLE-BLIND | FLUVASTATIN | HYPERCHOLESTEROLEMIA | CORONARY-HEART-DISEASE | SIMVASTATIN
Journal Article
Dental Materials Journal, ISSN 0287-4547, 2017
The aim of this study was to investigate properties of atelocollagen/gelatin complexes (AC/Gel) and their characteristics of sustained statin release, to... 
Regeneration | Fluvastatin | Gelatin | Atelocollagen | Controlled release
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 08/2019, Volume 136, pp. 104956 - 104956
The objective of present study was to develop hydrogel based nanoemulsion (NE) drug delivery system for transdermal delivery and evaluate its potential in... 
Osteoporosis | Nanoemulsion gel | Fluvastatin | Transdermal | VITRO | HYDROGELS | DRUG-DELIVERY | PHARMACOLOGY & PHARMACY | MECHANISMS | RELEASE | FORMULATION | STATINS
Journal Article
Journal of Clinical Biochemistry and Nutrition, ISSN 0912-0009, 01/2019, Volume 64, Issue 1, pp. 20 - 26
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 8, pp. 1238 - 1246
Bisphosphonates and statins are known to have antitumor activities against different types of cancer cell lines. In the present study, we investigated the... 
Journal Article
Monaldi Archives for Chest Disease - Cardiac Series, ISSN 1122-0643, 09/2010, Volume 74, Issue 3, pp. 147 - 149
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2017, Volume 70, Issue 16, pp. C47 - C47
The aim of this research is to evaluate the effects of Fluvastatin on cardiac sympathetic nerve remodeling and the electrophysiological characteristics of SCG... 
Ischemia | Analysis | Fluvastatin | Heart | Rabbits | Myocardial ischemia | Heart diseases | Variance analysis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.